Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • July 2016 •
  • 161 pages •
  • Report ID: 4035402 •
  • Format: PDF
Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response measures and unattractive dosing.

This report addresses the following questions:
- How do access restrictions for prostate cancer drugs differ across markets and why?
- Which clinical trial comparators and outcomes are necessary for approval and uptake in each market?
- What impact, if any, will value assessment tools have on US reimbursement patterns?
- When and where are risk-sharing agreements useful in gaining market access?
- What are US and EU payers’ and physicians’ opinions on drugs targeting non-metastatic CRPC or metastatic HSPC?
- Which vaccines have a chance for uptake and reimbursement in US and EU markets?
- What does the future hold for radiotherapy Xofigo?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.